

CureVac AG - Friedrich-Miescher-Str. 15 • 72076 Tübingen, Germany

European Commission
Rue de la Loi 200/ Wetstraat 200
1049 Bruxelles/Brussel
Belgium

CureVac AG

T +49 7071

F +49 7071

Page 1

CONFIDENTIAL

Dear [REDACTED]

We are pleased to present the attached summary of [REDACTED] we have exchange with your team multiple times in the past month and have had the chance to present the needs of the company.

We have structured the document in 4 sections:

1. [REDACTED]
2. [REDACTED]
3. [REDACTED]
4. [REDACTED]

Our Vaccine is based on mRNA technology: we encode the structure for the full length spike Coronavirus protein on mRNA and bring this genetic information to human cells. Upon intramuscular injection, the cells uptake the information and intracellular machinery expresses the spike protein. At no time do we handle active virus, nor use adenoviruses and thus can produce multiple products in the same manufacturing plant.

With our proprietary optimization process, CureVac's vaccine technology secures both high levels of protein produced in the cells and appropriate activation of innate immunity. This helps to activate immune system in an efficient and natural way.

Our SARS-CoV-2 preclinical data demonstrates (Figure below) a [REDACTED]

CureVac AG
Friedrich-Miescher-Strasse 15
72076 Tübingen, Germany
T +49 7071 9883-0
F +49 7071 9883-1101
info@curevac.com
www.curevac.com

Management Board
Dr. Ingmar Hoerr (Chairman),
Dr. Franz-Werner Haas, Dr. Maholz Fohn-Mieczek,
Dr. Florian von der Mülbe, Pierre Kemu a
Chairman of the Supervisory Board
Jean, Stéphanne

Registered Seat
Local Court Stuttgart
HRA 754041

1.

CureVac will manufacture up to company needs

The objective is to have as much vaccine at hand when it is potentially approved.

We expect to spend up to

This latter figure will depend on the dose that is established in the clinic and consequent needed dilution.

Assuming the optimum dose determined in the clinical trial is the batches produced

this certainly depends on the concrete dose per vaccination finally determined on the basis of the clinical data.

In the short run, CureVac will present the vaccine in a [REDACTED]

Should the vaccine be successful, the Company will [REDACTED]

As previously discussed, discussions with [REDACTED] only to [REDACTED]

The aim is not [REDACTED]

This pre-investment would then to be [REDACTED] when the vaccine will be made available in the market.

2. [REDACTED]

The company expects to shortly start [REDACTED] Regular exchanges with the [REDACTED] authorities has helped the company define the [REDACTED] curevac has reached out to [REDACTED]

To be sufficiently powered, it is expected that such [REDACTED]

potentially [REDACTED] The company expects this international trial to [REDACTED] CureVac has started the preparation [REDACTED]

3. [REDACTED]

CureVac needs support now on:

- [REDACTED]
- [REDACTED]
- [REDACTED]

4. [REDACTED]

CureVac would recognise the [REDACTED]

- [REDACTED]
- [REDACTED]
- [REDACTED]

- [REDACTED]
- [REDACTED]
- [REDACTED]
 - [REDACTED]
 - [REDACTED]
 - [REDACTED]

We understand that the EC has an [REDACTED]

We look forward to exchanging at your earliest convenience,

Yours Sincerely,

[REDACTED]